Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2023-04-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
新乡拓新药业股份有限公司2022年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" which translates to "Audit Report" for the fiscal year 2022. It contains detailed audit opinions, basis for audit opinions, key audit matters, responsibilities of management and auditors, and extensive financial statements including consolidated and parent company balance sheets, income statements, and cash flow statements. The content is comprehensive and includes auditor's signatures and detailed notes, indicating it is the full audit report rather than a brief announcement or certification. The length is substantial (15,000 characters), and the document is not merely announcing the availability of a report but contains the full audit findings and financial data. Therefore, it fits the category of Audit Report / Information (AR). FY 2022
2023-04-25 Chinese
新乡拓新药业股份有限公司2022年12月31日内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Assurance Report) and includes detailed content about the company's internal control evaluation for the fiscal year ending December 31, 2022. It is issued by a certified public accounting firm and addresses the effectiveness of internal controls related to financial reporting. The document also contains an "内部控制自我评价报告" (Internal Control Self-Evaluation Report) by the company. The content is extensive (15,000 characters) and includes detailed descriptions of internal control structures, risk assessments, control activities, and supervisory mechanisms. This type of document is a standalone audit-related report focusing on internal control effectiveness, not a full annual report or financial statement. It is not a mere announcement or certification letter but a substantive audit report on internal controls. Therefore, it fits the category of Audit Report / Information (AR). FY 2022
2023-04-25 Chinese
2022年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as "新乡拓新药业股份有限公司2022年年度报告摘要" which translates to "Xinxiang Tuoxin Pharmaceutical Co., Ltd. 2022 Annual Report Summary." It contains detailed information about the company's business, core technologies, financial data for the year 2022, shareholder information, and future outlook. It includes audited financial figures, mentions the auditor's opinion, and discusses risks and management plans. The length is substantial (15,000 characters) and it is not merely an announcement of a report but contains substantive financial and operational data. Therefore, this document is an Annual Report (10-K equivalent). FY 2022
2023-04-25 Chinese
关于提请股东大会授权董事会办理小额快速融资相关事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding a proposal to the shareholders' meeting to authorize the board to handle matters related to a small-scale rapid financing (private placement of shares). It details the authorization scope, issuance conditions, pricing, use of proceeds, and other procedural matters. The document is not a financial report but a notice about a capital raising authorization to be approved by shareholders. It is relatively short (2915 characters) and serves as a formal announcement of a financing proposal rather than the financing update itself or a report containing financial data. Therefore, it fits best under Capital/Financing Update (CAP).
2023-04-25 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2022 Annual Report" of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, and financial statements. The document includes audited financial statements and an audit report, as well as comprehensive management discussion and analysis. The length of the document (15,000 characters) and the detailed content confirm it is the full annual report, not just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-04-25 Chinese
2022年度监事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2022年度监事会工作报告" which translates to "2022 Supervisory Board Work Report". It details the supervisory board's activities, meetings, oversight of company operations, financial supervision, internal control, related party transactions, and plans for 2023. It is a report from the supervisory board rather than a full annual report or financial statement. The content focuses on governance and supervisory activities rather than financial results or audit opinions. It is not an announcement or a brief summary but a detailed report on supervisory work. This fits best under the category of Board/Management Information (MANG), which includes announcements related to company board or senior management activities and reports on their work. The document length is under 5,000 characters, but it is a substantive report, not just an announcement of a report. Therefore, the classification is MANG with high confidence.
2023-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.